Avidity Biosciences Q2 EPS $(0.65) Beats $(0.79) Estimate, Collaboration Revenue $2.04M Miss $2.64M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences (NASDAQ:RNA) reported Q2 EPS of $(0.65), beating the $(0.79) estimate, but missed revenue expectations with $2.04M against the $2.64M estimate.
August 09, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avidity Biosciences reported better-than-expected EPS of $(0.65) but missed revenue estimates with $2.04M. The EPS beat may provide short-term support, but the revenue miss could weigh on the stock.
The EPS beat is a positive sign and may provide short-term support for the stock. However, the significant revenue miss could offset this positive impact, leading to potential volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100